Press release
Onychomycosis Pipeline Drugs 2025 Report: Emerging Drugs, Innovative Therapies, Clinical Trial Updates, and Top Companies
Curious about the latest updates in the Onchomycosis Pipeline? Click here to explore the therapies and trials making headlines @ Onchomycosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Onchomycosis Pipeline Report
* In September 2025, Vanda Pharmaceuticals announced a study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.
* DelveInsight's Onchomycosis Pipeline report depicts a robust space with 11+ active players working to develop 11+ pipeline therapies for Onchomycosis treatment.
* The leading Onchomycosis Companies such as Blueberry Therapeutics, AmtixBio, Mycovia Pharmaceuticals, Polichem, Onicor, Nihon Nohyaku and others.
* Promising Onchomycosis Therapies such as Tavaborole 5% Topical Solution, MOB015B, Terbinafine HCl, Amorolfine 5%, Amorolfine, and others.
Want to know which companies are leading innovation in Onchomycosis? Dive into the full pipeline insights @ Onchomycosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Onchomycosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Onchomycosis Pipeline Report also highlights the unmet needs with respect to the Onchomycosis.
Onchomycosis Overview
Onychomycosis is a fungal infection of the nail, typically caused by dermatophytes, which affects approximately 10% of the US population. The disease can have significant negative consequences for patients, including pain, discomfort, and potential impacts on work and social lives. The primary pathogens responsible for onychomycosis are dermatophytes, such as Trichophyton rubrum, Epidermophyton floccosum, and Trichophyton mentagrophytes. Other organisms, including yeasts like Candida albicans and nondermatophyte molds, can also be implicated. The infection can manifest in various forms, including distal subungual onychomycosis, which is the most common type, characterized by invasion of the nail bed and underside of the nail plate.
Onchomycosis Emerging Drugs Profile
* BB2603: Blueberry Therapeutics
Blueberry is developing a new topical antifungal spray formulation of terbinafine (BB2603om) for the treatment of onychomycosis using our nanodelivery platform technology. The aim is to apply the spray directly to the nail, and through enhanced delivery of the active substance through the nail, to match the cure rates of the more effective oral formulations in a topical medicine, without the associated safety concerns. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Onychomycosis.
* ATB-1651: AmtixBio
ATB-1651 is a potential first-in-class drug candidate targeting fungal cell wall components. It is a new drug candidate that acts quickly on virulent fungi, can reliably kill fungi, and reliably suppresses the creation of resistant bacteria. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Onychomycosis.
If you're tracking ongoing Onchomycosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Onchomycosis Treatment Drugs [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Onchomycosis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Onchomycosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onchomycosis Treatment.
* Onchomycosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Onchomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Onchomycosis market.
Onchomycosis Companies
Blueberry Therapeutics, AmtixBio, Mycovia Pharmaceuticals, Polichem, Onicor, Nihon Nohyaku and others.
Onchomycosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Onchomycosis Products have been categorized under various Molecule types such as,
* Monoclonal antibody
* Small molecule
* Peptide
From emerging drug candidates to competitive intelligence, the Onchomycosis Pipeline Report covers it all - check it out now @ Onchomycosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Onchomycosis Pipeline Report
* Coverage- Global
* Onchomycosis Companies- Blueberry Therapeutics, AmtixBio, Mycovia Pharmaceuticals, Polichem, Onicor, Nihon Nohyaku and others.
* Onchomycosis Therapies- Tavaborole 5% Topical Solution, MOB015B, Terbinafine HCl, Amorolfine 5%, Amorolfine, and others.
* Onchomycosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Onchomycosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Onchomycosis Treatment landscape in this detailed analysis @ Onchomycosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Onychomycosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Onychomycosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BB2603: Blueberry Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ATB-1651: AmtixBio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Onychomycosis Key Companies
* Onychomycosis Key Products
* Onychomycosis- Unmet Needs
* Onychomycosis- Market Drivers and Barriers
* Onychomycosis- Future Perspectives and Conclusion
* Onychomycosis Analyst Views
* Onychomycosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=onychomycosis-pipeline-drugs-2025-report-emerging-drugs-innovative-therapies-clinical-trial-updates-and-top-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Onychomycosis Pipeline Drugs 2025 Report: Emerging Drugs, Innovative Therapies, Clinical Trial Updates, and Top Companies here
News-ID: 4226090 • Views: …
More Releases from ABNewswire
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg
The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence.
A clearer view of pentest vs red team helps organisations make better…
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen …
West Chester, PA - Suburban Solutions [https://suburbansolutions.com/], a highly trusted and fast-growing moving company serving the Greater Philadelphia and Washington, DC regions, is proud to announce the opening of its newest location at 1271 Upton Cir, West Chester, PA 19380. This expansion marks an important step in the company's ongoing mission to provide dependable and accessible relocation support to more communities across Pennsylvania.
With this new branch, Suburban Solutions Moving aims…
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Sup …
Shenzhen LSLONG Garments Co., Ltd., a global leader in apparel manufacturing, has officially unveiled its new Premium Custom Polo Shirt [https://www.lslt-shirt.com/polo-shirt-categories/] Collection, combining advanced fabrics, innovative designs, and end-to-end customization solutions. This launch underscores LSLONG's 25 years of experience delivering high-quality OEM and ODM apparel services to brands across more than 50 countries. The collection aims to empower brands with versatile, stylish, and performance-driven Polo shirts while providing comprehensive support…
Arteestry Creations Plus Brings Unique Customizable Designs to Over 50 Product C …
Arteestry Creations Plus offers creative custom designs across an extensive range of products from apparel to home goods to magnets, serving customers seeking personalized items for holidays, special occasions, and everyday use. The growing e-commerce brand combines artistic creativity with broad product versatility, featuring licensed collections from Disney, Pixar, Marvel, and Star Wars alongside original designs that can be applied across different product types upon customer request.
Arteestry Creations Plus has…
More Releases for Onchomycosis
Podiatry Lasers Market Emerging Top Key Players to Watch- Fotona, HCPC, Norfolk …
Podiatry refers to the medical care and treatment of foot, ankle and lower extremity disorders. The use of laser in podiatry is prevailing in the market owing to its specialized features such as non-invasive, drug free, safe and effective way of treatment. The podiatry laser treatment method is painless procedure for treating conditions that require prolonged treatment or are difficult to manage. The podiatry laser includes treatment for verrucae, scar…
Cell Lysis Market: A Comprehensive Insight with Market Share, Challenges and Top …
“Global Cell Lysis Market Report 2018” report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.
Global Cell Lysis Market Overview:
The report spread across 122 pages is an overview of the Global Cell Lysis Market Report…
